LifeVac Becomes First FDA-Authorized Suction Anti-Choking Device for Emergency Airway Clearance
核心洞察
LifeVac (搜索) has received FDA De Novo classification as the first and only suction anti-choking (搜索) device authorized for use as a second-line treatment when basic life support protocols fail.
The device is classified as a Class II medical device under 21 CFR 874.5400 and is approved for single-use, non-invasive airway clearance in adults and children aged one year and above.
With over 5,500 documented successful saves worldwide, the FDA authorization establishes a clear regulatory framework for suction anti-choking (搜索) devices in emergency settings.
LifeVac (搜索) has achieved a significant regulatory milestone by becoming the first and only airway clearance device to receive FDA authorization for use as a second-line treatment in choking (搜索) emergencies. The FDA granted De Novo classification under 21 Code of Federal Regulations (CFR) 874.5400, establishing the device type "suction anti-choking device as a second-line treatment."
FDA Classification and Regulatory Framework
The FDA has classified LifeVac (搜索) as a Class II medical device, defining it as intended to resolve choking (搜索) in victims with complete airway obstruction (搜索) through the application of suction. The device is specifically authorized for use as a second-line treatment in emergencies when initial basic life support (BLS) choking protocols have not been successful.
According to the FDA determination, Class II classification combined with general and special controls provides reasonable assurance regarding the effectiveness and safety of the device in its intended application. The authorization establishes a clear regulatory framework for suction anti-choking (搜索) devices used as second-line treatment.
Device Specifications and Usage
LifeVac (搜索) is approved as a single-use, non-powered, non-invasive airway clearance device designed for both adult and pediatric individuals aged one year and above. The device can be operated by either lay persons or medical professionals who are at least 18 years old, making it accessible for use across various emergency scenarios.
Potential settings for use include nursing homes, homes, schools, and restaurants, providing broad applicability for choking (搜索) emergencies in both professional and domestic environments.
Clinical Evidence and Global Impact
The device has documented over 5,500 successful saves worldwide, providing substantial real-world evidence of its effectiveness. In Australia, LifeVac (搜索) has undergone extensive clinical review by the Therapeutic Goods Administration (TGA) during a two-year post-market review and is listed as a Class 1 (low-risk) medical device under ARTG#285082.
Arthur Lih, LifeVac (搜索) founder and CEO, stated: "As stated in the order, LifeVac is intended to be used after a BLS choking (搜索) protocol fails. This classification creates a clear regulatory framework for suction anti-choking devices used as a second-line treatment."
International Regulatory Status
Beyond FDA authorization, LifeVac (搜索) is registered with multiple regulatory agencies globally, including the Australian Register of Therapeutic Goods (ARTG) and the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. This international recognition supports the device's safety profile and clinical utility across different healthcare systems.
Market Implementation
Under the FDA De Novo order, LifeVac (搜索) may immediately market its suction anti-choking (搜索) device in accordance with the De Novo request, provided it adheres to all outlined general and special controls set by the FDA. The device is already deployed in pre-schools, daycare centers, schools, residential aged care facilities, disability services, businesses, and homes across Australia, with rollout by councils and organizations continuing to expand.
Simon Gould, Owner of LifeVac (搜索) Australia, noted that the FDA authorization addresses previous barriers to adoption: "In Australia, we have had critics claim that their barrier to their adoption of the LifeVac has been the FDA. This excuse can no longer be used, with the FDA authorisation of LifeVac through a thoroughly evidenced de novo application."